輸入代號或公司名稱後按 Enter
4164

承業醫

+0.05 (+0.20%)最後更新 2026-09-15
台灣 · 上市 · 生技醫療業
25.40313成交張數21.71本益比0.66股價淨值比4.37%殖利率2026-09-15資料日期

綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該科目 ÷ 營業收入

營業收入20254,398年增 +22.2%
毛利率202526.1%最新一期
營業利益率20259.0%最新一期
每股盈餘20251.00年增 -1.0%
會計項目走勢20212022202320242025
營業收入合計100.0%100.0%100.0%100.0%100.0%
營業成本合計65.2%69.7%72.4%78.9%73.9%
營業毛利(毛損)34.8%30.3%27.6%21.1%26.1%
營業毛利(毛損)淨額34.8%30.3%27.6%21.1%26.1%
推銷費用5.0%6.2%5.6%7.5%11.0%
管理費用9.6%8.0%6.1%7.0%5.8%
預期信用減損損失(利益)0.0%0.1%0.0%-0.1%0.3%
營業費用合計14.6%14.3%11.7%14.5%17.1%
營業利益(損失)20.2%16.0%15.8%6.6%9.0%
利息收入0.4%0.4%0.5%0.7%0.5%
其他收入0.4%0.4%0.2%1.5%0.5%
其他利益及損失淨額1.3%1.8%0.1%0.1%-0.1%
財務成本淨額2.6%2.4%2.3%2.7%2.6%
採用權益法認列之關聯企業及合資損益之份額淨額0.4%-0.0%0.0%0.0%-0.1%
營業外收入及支出合計-0.1%0.3%-1.4%-0.4%-1.9%
稅前淨利(淨損)20.1%16.3%14.4%6.2%7.1%
所得稅費用(利益)合計4.5%3.2%3.5%1.1%2.0%
繼續營業單位本期淨利(淨損)15.6%13.1%11.0%5.1%5.1%
本期淨利(淨損)15.6%13.1%11.0%5.1%5.1%
透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益-0.2%-0.1%0.2%0.1%-0.4%
不重分類至損益之項目:-0.2%-0.1%0.2%0.1%-0.4%
國外營運機構財務報表換算之兌換差額-0.2%0.3%-0.1%0.4%-0.1%
與可能重分類之項目相關之所得稅0.0%0.0%0.0%-0.0%0.0%
後續可能重分類至損益之項目:-0.2%0.3%-0.1%0.4%-0.1%
其他綜合損益(淨額)-0.4%0.3%0.0%0.5%-0.4%
本期綜合損益總額15.2%13.3%11.0%5.6%4.7%
母公司業主(淨利∕損)15.6%12.0%10.8%4.7%4.2%
非控制權益(淨利∕損)-0.1%1.1%0.2%0.4%0.9%
母公司業主(綜合損益)15.3%12.3%10.8%5.2%3.8%
非控制權益(綜合損益)-0.1%1.1%0.2%0.4%0.9%
基本每股盈餘0.1%0.1%0.1%0.0%0.0%
繼續營業單位淨利(淨損)0.0%0.0%0.0%0.0%0.0%
稀釋每股盈餘0.1%0.1%0.1%0.0%0.0%

金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。